EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyseSystematische Übersicht

Vonoprazan‐amoxicillin dual therapy versus bismuth‐containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis

Ben-Gang Zhou iD, Xin Jiang, Yan-Bing Ding, Qiang She, Yao-Yao Li

Helicobacter · 2024

DOI: 10.1111/hel.13040 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Helicobacter, 2024. Verfasst von Ben-Gang Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Amoxicillin, Anti-Bacterial Agents, Bismuth, Helicobacter Infections. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Major Public Health Projects in Yangzhou: Screening projects of early gastrointestinal diseases (2018), the Strengthening Health Care via Science and Education Project and Clinical Medical Innovation Platform Foundation of Yangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Recently, vonoprazan‐amoxicillin (VA) dual therapy has been reported as a promising approach for Helicobacter pylori ( H. pylori ) eradication. However, the effects of VA therapy versus bismuth‐containing quadruple therapy (BQT) on H. pylori eradication remains unclear. The objective of this meta‐analysis was to compare the effects of VA dual therapy with BQT for H. pylori eradication.

Methods

A comprehensive search of the literature was conducted from the beginning to September 2023, utilizing PubMed, Embase, the Cochrane Library and Web of Science database. A random‐effects model was used to perform a meta‐analysis to determine the pooled relative risk (RR) with 95% confidence intervals (CIs). Moreover, trial sequential analysis (TSA) was conducted to evaluate the conclusiveness of the H. pylori eradication rate.

Results

Six randomized controlled trials (RCTs) with 1233 patients were included. The VA therapy has similar eradication rate (ITT analysis: 87% vs. 85.7%, RR = 1.01, 95% CI: 0.93–1.09, p = 0.84; PP analysis: 92.5% vs. 93.2%, RR = 1.00, 95% CI: 0.94–1.06, p = 0.97) and compliance (RR = 1.01, 95% CI: 0.99–1.03, p = 0.32) compared to BQT. The VA therapy group had a significantly lower incidence of total adverse events than the BQT group (16.3% vs. 40.0%, RR = 0.45, 95% CI: 0.37–0.55, p < 0.00001). The TSA result showed that the effect was conclusive.

Conclusions

Current evidence indicated that VA therapy is just as successful as BQT in eliminating H. pylori , yet it has fewer adverse events and similar compliance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmoxicillinAnti-Bacterial AgentsBismuthHelicobacter InfectionsHelicobacter pyloriSulfonamidesHumansDrug Therapy, CombinationProton Pump InhibitorsRandomized Controlled Trials as TopicTreatment OutcomePyrroles

Stichwörter der Autor:innen

Helicobacter pyloriamoxicillindual therapymeta-analysisvonoprazan

Substanzen

AmoxicillinAnti-Bacterial AgentsBismuthProton Pump InhibitorsSulfonamides1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanaminePyrroles

Autor:innen und Institutionen

  • Dalian Medical University, Dalian, China.
  • Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.

ORCID-Profile: Ben-Gang Zhou

Förderung

  • National Natural Science Foundation of China
  • the Major Public Health Projects in Yangzhou: Screening projects of early gastrointestinal diseases (2018)
  • the Strengthening Health Care via Science and Education Project and Clinical Medical Innovation Platform Foundation of Yangzhou

Zitieren

APA

Zhou, B. G., Jiang, X., Ding, Y. B., She, Q., & Li, Y. Y. (2024). Vonoprazan‐amoxicillin dual therapy versus bismuth‐containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis. Helicobacter. https://doi.org/10.1111/hel.13040

Vancouver

Zhou BG, Jiang X, Ding YB, She Q, Li YY. Vonoprazan‐amoxicillin dual therapy versus bismuth‐containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis. Helicobacter. 2024. doi:10.1111/hel.13040

BibTeX
@article{Zhou2024,
  author = {Zhou, Ben-Gang and Jiang, Xin and Ding, Yan-Bing and She, Qiang and Li, Yao-Yao},
  title = {Vonoprazan‐amoxicillin dual therapy versus bismuth‐containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis},
  journal = {Helicobacter},
  year = {2024},
  doi = {10.1111/hel.13040}
}
Kostenlos starten →